-
11.发明申请MICROORGANISMS FOR THE PRODUCTION OF 1,4-BUTANEDIOL, 4-HYDROXYBUTANAL, 4-HYDROXYBUTYRYL-COA, PUTRESCINE AND RELATED COMPOUNDS, AND METHODS RELATED THERETO 有权用于生产1,4-丁二醇，4-羟基吡啶，4-羟基丁酰氯，聚氨酯和相关化合物的微生物及其相关方法公开(公告)号：US20110129899A1
公开(公告)日：2011-06-02
申请号：US12904130
申请日：2010-10-13
Applicant: Robert Haselbeck , John D. Trawick , Wei Niu , Anthony P. Burgard
Inventor： Robert Haselbeck , John D. Trawick , Wei Niu , Anthony P. Burgard
IPC: C12N1/00
CPC classification number: C12P7/18 , C12P7/24 , C12P7/42 , C12P13/001 , C12P19/40
Abstract: The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO), 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway comprising at least one exogenous nucleic acid encoding a BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway enzyme expressed in a sufficient amount to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine.
Abstract translation: 本发明提供了包含1,4-丁二醇（BDO），4-羟基丁酰辅酶A，4-羟基丁醛或腐胺途径的非天然存在的微生物，其包含至少一种编码BDO，4-羟基丁酰辅酶A， 表达量足以产生BDO，4-羟基丁酰辅酶A，4-羟基丁醛或腐胺的β-羟基丁酸或腐胺途径酶，并进一步优化BDO的表达。 本发明另外提供了使用这些微生物生产BDO，4-羟基丁酰辅酶A，4-羟基丁醛或腐胺的方法。
-
公开(公告)号：US20070178111A1
公开(公告)日：2007-08-02
申请号：US11636379
申请日：2006-12-08
Applicant: Vickie Brown-Driver , Kedar GC , John Finn , Robert Haselbeck , Mark Hilgers , Karen Shaw , Mark Stidham
Inventor： Vickie Brown-Driver , Kedar GC , John Finn , Robert Haselbeck , Mark Hilgers , Karen Shaw , Mark Stidham
IPC: A61K48/00 , A61K39/40 , A61K31/43 , A61K31/545
CPC classification number: A61K31/43 , A61K31/545 , A61K39/40 , A61K45/06 , Y02A50/469 , Y02A50/47 , Y02A50/482 , Y02A50/484 , A61K2300/00
Abstract: The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a β-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, MurD, MurE, MurF, MurG, MraY, and UppS. Further provided is a method of discovering synergists for antibiotics including: a) expressing in a cell an antisense nucleic acid against a nucleic acid encoding a gene product so as to reduce the activity or amount of the gene product in the cell, thereby producing a cell sensitized to an antibiotic; b) characterizing the sensitization of the cell to the antibiotic and selecting pairs of antibiotics and genes that result in antibiotic efficacy at one-fifth or less the concentration required in the absence of the antisense gene; c) screening for chemical compounds that inhibit the gene product corresponding to the selected synergistic gene; and d) selecting or creating chemical analogs that inhibit the gene product corresponding to the selected synergistic gene such that the inhibition occurs in the bacteria.
Abstract translation: 本发明提供了用于治疗人和动物细菌感染的药物组合物，其包括对有需要的人或动物施用β-内酰胺抗生素和任何细菌肽聚糖生物合成酶的抑制剂的抗菌有效组合，特别是GlmU ，GlmU，MurA，MurB，MurC，MurD，MurE，MurF，MurG，MraY和UppS。 进一步提供了发现抗生素增效剂的方法，包括：a）在细胞中表达反义核酸对抗编码基因产物的核酸，以降低细胞中基因产物的活性或数量，从而产生细胞 对抗生素敏感; b）表征细胞对抗生素的致敏性，并选择一组抗生素和基因，其抗生素效力为不存在反义基因所需浓度的五分之一或更低。 c）筛选抑制与所选协同基因相对应的基因产物的化合物; 和d）选择或产生抑制与所选择的协同基因相对应的基因产物的化学类似物，使得在细菌中发生抑制。
-
13.发明授权Microorganisms for the production of 1,4-butanediol, 4-hydroxybutanal, 4-hydroxybutyryl-CoA, putrescine and related compounds, and methods related thereto 有权用于生产1,4-丁二醇，4-羟基丁醛，4-羟基丁酰辅酶A，腐胺及相关化合物的微生物及其相关方法公开(公告)号：US08377667B2
公开(公告)日：2013-02-19
申请号：US13109732
申请日：2011-05-17
Applicant: Robert Haselbeck , John D. Trawick , Wei Niu , Anthony P. Burgard
Inventor： Robert Haselbeck , John D. Trawick , Wei Niu , Anthony P. Burgard
CPC classification number: C12P7/18 , C12P7/24 , C12P7/42 , C12P13/001 , C12P19/40
Abstract: The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO), 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway comprising at least one exogenous nucleic acid encoding a BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway enzyme expressed in a sufficient amount to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine.
Abstract translation: 本发明提供了包含1,4-丁二醇（BDO），4-羟基丁酰辅酶A，4-羟基丁醛或腐胺途径的非天然存在的微生物，其包含至少一种编码BDO，4-羟基丁酰辅酶A， 表达量足以产生BDO，4-羟基丁酰辅酶A，4-羟基丁醛或腐胺的β-羟基丁酸或腐胺途径酶，并进一步优化BDO的表达。 本发明另外提供了使用这些微生物生产BDO，4-羟基丁酰辅酶A，4-羟基丁醛或腐胺的方法。
-
14.发明授权Microorganisms for the production of 1,4-butanediol, 4-hydroxybutanal, 4-hydroxybutyryl-coa, putrescine and related compounds, and methods related thereto 有权用于生产1,4-丁二醇，4-羟基丁醛，4-羟基丁酰辅酶，腐胺及相关化合物的微生物及其相关方法公开(公告)号：US08377666B2
公开(公告)日：2013-02-19
申请号：US12904130
申请日：2010-10-13
Applicant: Robert Haselbeck , John D. Trawick , Wei Niu , Anthony P. Burgard
Inventor： Robert Haselbeck , John D. Trawick , Wei Niu , Anthony P. Burgard
CPC classification number: C12P7/18 , C12P7/24 , C12P7/42 , C12P13/001 , C12P19/40
Abstract: The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO), 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway comprising at least one exogenous nucleic acid encoding a BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway enzyme expressed in a sufficient amount to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine.
Abstract translation: 本发明提供了包含1,4-丁二醇（BDO），4-羟基丁酰辅酶A，4-羟基丁醛或腐胺途径的非天然存在的微生物，其包含至少一种编码BDO，4-羟基丁酰辅酶A， 表达量足以产生BDO，4-羟基丁酰辅酶A，4-羟基丁醛或腐胺的β-羟基丁酸或腐胺途径酶，并进一步优化BDO的表达。 本发明另外提供了使用这些微生物生产BDO，4-羟基丁酰辅酶A，4-羟基丁醛或腐胺的方法。
-
Patent Agency Ranking
公开(公告)号：US08298543B2
公开(公告)日：2012-10-30
申请号：US13102856
申请日：2011-05-06
Applicant: Vickie Brown-Driver , Kedar GC , John M. Finn , Robert Haselbeck , Mark Hilgers , Karen Shaw , Mark Stidham
Inventor： Vickie Brown-Driver , Kedar GC , John M. Finn , Robert Haselbeck , Mark Hilgers , Karen Shaw , Mark Stidham
CPC classification number: A61K31/43 , A61K31/545 , A61K39/40 , A61K45/06 , Y02A50/469 , Y02A50/47 , Y02A50/482 , Y02A50/484 , A61K2300/00
Abstract: The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a β-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, MurD, MurE, MurF, MurG, MraY, and UppS. Further provided is a method of discovering synergists for antibiotics including: a) expressing in a cell an antisense nucleic acid against a nucleic acid encoding a gene product so as to reduce the activity or amount of the gene product in the cell, thereby producing a cell sensitized to an antibiotic; b) characterizing the sensitization of the cell to the antibiotic and selecting pairs of antibiotics and genes that result in antibiotic efficacy at one-fifth or less the concentration required in the absence of the antisense gene; c) screening for chemical compounds that inhibit the gene product corresponding to the selected synergistic gene; and d) selecting or creating chemical analogs that inhibit the gene product corresponding to the selected synergistic gene such that the inhibition occurs in the bacteria.
Abstract translation: 本发明提供了一种可用于治疗人和动物细菌感染的药物组合物，其包括对有需要的人或动物施用抗生素有效组合的β-内酰胺抗生素和任何细菌肽聚糖生物合成酶的抑制剂，特别是 GlmU，GlmU，MurA，MurB，MurC，MurD，MurE，MurF，MurG，MraY，和UppS。 进一步提供了发现抗生素增效剂的方法，包括：a）在细胞中表达反义核酸对编码基因产物的核酸，以降低细胞中基因产物的活性或数量，从而产生细胞 对抗生素敏感; b）表征细胞对抗生素的致敏性，并选择一组抗生素和基因，其抗生素效力为不存在反义基因所需浓度的五分之一或更低。 c）筛选抑制与所选协同基因相对应的基因产物的化合物; 和d）选择或产生抑制与所选择的协同基因相对应的基因产物的化学类似物，使得在细菌中发生抑制。
-
16.发明申请公开(公告)号：US20120225463A1
公开(公告)日：2012-09-06
申请号：US13361799
申请日：2012-01-30
Applicant: Stephen J. Van Dien , Anthony P. Burgard , Robert Haselbeck , Catherine J. Pujol-Baxley , Wei Niu , John D. Trawick , Harry Yim , Mark J. Burk , Robin E. Osterhout , Jun Sun
Inventor： Stephen J. Van Dien , Anthony P. Burgard , Robert Haselbeck , Catherine J. Pujol-Baxley , Wei Niu , John D. Trawick , Harry Yim , Mark J. Burk , Robin E. Osterhout , Jun Sun
CPC classification number: C12P7/18 , C12N9/0006 , C12N9/0008 , C12N9/001 , C12N9/13 , C12N9/16 , C12N9/88 , C12N9/93 , C12N15/52
Abstract: The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO) pathway comprising at least one exogenous nucleic acid encoding a BDO pathway enzyme expressed in a sufficient amount to produce BDO and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO.
Abstract translation: 本发明提供了包含1,4-丁二醇（BDO）途径的非天然存在的微生物生物，其包含至少一种编码足够量的BDO途径酶的外源核酸以产生BDO并进一步优化用于BDO的表达。 本发明还提供了使用这种微生物生产BDO的方法。
-
公开(公告)号：US20110294774A1
公开(公告)日：2011-12-01
申请号：US13102856
申请日：2011-05-06
Applicant: Vickie Brown-Driver , Kedar GC , John M. Finn , Robert Haselbeck , Mark Hilgers , Karen Shaw , Mark Stidham
Inventor： Vickie Brown-Driver , Kedar GC , John M. Finn , Robert Haselbeck , Mark Hilgers , Karen Shaw , Mark Stidham
IPC: A61K31/545 , A61P31/04 , A61K31/43 , A61K31/431 , A61K31/546 , A61K31/5365
CPC classification number: A61K31/43 , A61K31/545 , A61K39/40 , A61K45/06 , Y02A50/469 , Y02A50/47 , Y02A50/482 , Y02A50/484 , A61K2300/00
Abstract: The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a β-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, MurD, MurE, MurF, MurG, MraY, and UppS. Further provided is a method of discovering synergists for antibiotics including: a) expressing in a cell an antisense nucleic acid against a nucleic acid encoding a gene product so as to reduce the activity or amount of the gene product in the cell, thereby producing a cell sensitized to an antibiotic; b) characterizing the sensitization of the cell to the antibiotic and selecting pairs of antibiotics and genes that result in antibiotic efficacy at one-fifth or less the concentration required in the absence of the antisense gene; c) screening for chemical compounds that inhibit the gene product corresponding to the selected synergistic gene; and d) selecting or creating chemical analogs that inhibit the gene product corresponding to the selected synergistic gene such that the inhibition occurs in the bacteria.
Abstract translation: 本发明提供了一种可用于治疗人和动物细菌感染的药物组合物，其包括对有需要的人或动物施用抗生素有效组合的β-内酰胺抗生素和任何细菌肽聚糖生物合成酶的抑制剂，特别是 GlmU，GlmU，MurA，MurB，MurC，MurD，MurE，MurF，MurG，MraY和UppS。 进一步提供了发现抗生素增效剂的方法，包括：a）在细胞中表达反义核酸对抗编码基因产物的核酸，以降低细胞中基因产物的活性或数量，从而产生细胞 对抗生素敏感; b）表征细胞对抗生素的致敏性，并选择一组抗生素和基因，其抗生素效力为不存在反义基因所需浓度的五分之一或更低。 c）筛选抑制与所选协同基因相对应的基因产物的化合物; 和d）选择或产生抑制与所选择的协同基因相对应的基因产物的化学类似物，使得在细菌中发生抑制。
-
公开(公告)号：US08021665B2
公开(公告)日：2011-09-20
申请号：US11636379
申请日：2006-12-08
Applicant: Vickie Brown-Driver , Kedar GC , John M. Finn , Robert Haselbeck , Mark Hilgers , Karen Shaw , Mark Stidham
Inventor： Vickie Brown-Driver , Kedar GC , John M. Finn , Robert Haselbeck , Mark Hilgers , Karen Shaw , Mark Stidham
CPC classification number: A61K31/43 , A61K31/545 , A61K39/40 , A61K45/06 , Y02A50/469 , Y02A50/47 , Y02A50/482 , Y02A50/484 , A61K2300/00
Abstract: The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a β-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, MurD, MurE, MurF, MurG, MraY, and UppS. Further provided is a method of discovering synergists for antibiotics including: a) expressing in a cell an antisense nucleic acid against a nucleic acid encoding a gene product so as to reduce the activity or amount of the gene product in the cell, thereby producing a cell sensitized to an antibiotic; b) characterizing the sensitization of the cell to the antibiotic and selecting pairs of antibiotics and genes that result in antibiotic efficacy at one-fifth or less the concentration required in the absence of the antisense gene; c) screening for chemical compounds that inhibit the gene product corresponding to the selected synergistic gene; and d) selecting or creating chemical analogs that inhibit the gene product corresponding to the selected synergistic gene such that the inhibition occurs in the bacteria.
Abstract translation: 本发明提供了一种可用于治疗人和动物细菌感染的药物组合物，其包括对有需要的人或动物施用抗生素有效组合的β-内酰胺抗生素和任何细菌肽聚糖生物合成酶的抑制剂，特别是 GlmU，GlmU，MurA，MurB，MurC，MurD，MurE，MurF，MurG，MraY和UppS。 进一步提供了发现抗生素增效剂的方法，包括：a）在细胞中表达反义核酸对抗编码基因产物的核酸，以降低细胞中基因产物的活性或数量，从而产生细胞 对抗生素敏感; b）表征细胞对抗生素的致敏性，并选择一组抗生素和基因，其抗生素效力为不存在反义基因所需浓度的五分之一或更低。 c）筛选抑制与所选协同基因相对应的基因产物的化合物; 和d）选择或产生抑制与所选择的协同基因相对应的基因产物的化学类似物，使得在细菌中发生抑制。
-
19.发明申请MICROORGANISMS AND METHODS FOR THE COPRODUCTION 1,4-BUTANEDIOL AND GAMMA-BUTYROLACTONE 有权共聚1,4-丁二醇和γ-丁内酯的微生物和方法公开(公告)号：US20110217742A1
公开(公告)日：2011-09-08
申请号：US12940021
申请日：2010-11-04
Applicant: Jun Sun , Mark J. Burk , Anthony P. Burgard , Robin E. Osterhout , Wei Niu , John D. Trawick , Robert Haselbeck
Inventor： Jun Sun , Mark J. Burk , Anthony P. Burgard , Robin E. Osterhout , Wei Niu , John D. Trawick , Robert Haselbeck
IPC: C12P17/04
Abstract: The invention provides non-naturally occurring microbial organisms comprising 1,4-butanediol (14-BDO) and gamma-butyrolactone (GBL) pathways comprising at least one exogenous nucleic acid encoding a 14-BDO and GBL pathway enzyme expressed in a sufficient amount to produce 14-BDO and GBL. The invention additionally provides methods of using such microbial organisms to produce 14-BDO and GBL.
Abstract translation: 本发明提供包含1,4-丁二醇（14-BDO）和γ-丁内酯（GBL）途径的非天然存在的微生物生物，其包含至少一种编码14-BDO和GBL途径酶的外源核酸，其以足够的量表达， 生产14-BDO和GBL。 本发明另外提供了使用这种微生物生物来生产14-BDO和GBL的方法。
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.064 seconds)
